Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population

Canadian Journal of Ophthalmology

Volumn 45, Issue 4, 2010, Pages 381-385

  Qi, Hui Jun ^a   Li, Xiao Xin ^a   Tao, Yong ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Bevacizumab; Chinese population; Idiopathic choroidal neovascularization

Indexed keywords

BEVACIZUMAB; LEVOFLOXACIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; CASE STUDY; CHINESE; CONJUNCTIVAL HEMORRHAGE; CORNEA INJURY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; GLAUCOMA; HUMAN; IDIOPATHIC DISEASE; INTERVENTION STUDY; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA FOVEA; RETROSPECTIVE STUDY; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHOROIDAL NEOVASCULARIZATION; EPIDEMIOLOGY; ETHNOLOGY; INJECTION; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME; VITREOUS BODY; YOUNG ADULT;

ADOLESCENT; ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; INJECTIONS; MALE; MIDDLE AGED; RETREATMENT; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY; YOUNG ADULT;

EID: 84925581748     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/i10-019     Document Type: Article

References (20)

1. Spaide RF. Choroidal neovascularization in younger patients. Curr Opin Ophthalmol 1999;10:177-81.
2. Flaxel CJ. The use of systemic steroids and photodynamic treatment for choroidal neovascularisation in young patients. Br J Ophthalmol 2007;91:564-5.
3. Lindblom B, Andersson T. The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age. Ophthalmology 1998;105:1816-20. (Pubitemid 28509718)
4. Thomas MA, Grand MG, Williams DF, Lee CM, Pesin SR, Lowe MA. Surgical management of subfoveal choroidal neovascularization. Ophthalmology 1992;99:952-68.
5. Fujii GY, Pieramici DJ, Humayun MS, et al. Complications associated with limited macular translocation. Am J Ophthalmol 2000;130:751-62.
6. Reichel E, Berrocal AM, Ip M, et al. Transpupillary thermotherapy of occult subfoveal choroidal neovascularization in patients with age-related macular degeneration. Ophthalmology 1999;106:1908-14.
7. Spaide RF, Guyer DR, McCormick B, et al. External beam radiation therapy for choroidal neovascularization. Ophthalmology 1998;105:24-30. (Pubitemid 28070598)
8. Sickenberg M, Schmidt-Erfurth U, Miller JW, et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch Ophthalmol 2000;118:327-36.
9. Chan WM, Lam DS, Wong TH, et al. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 2003;110:2395-402.
10. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol 2008;145:249-56.
11. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007;27:439-44.
12. Donati MC, Virgili G, Bini A, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization in angioid streaks: a case series. Ophthalmologica 2009;223:24-7.
13. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: sixmonth results of a prospective pilot study. Ophthalmology 2007;114:2190-6.
14. Mandal S, Garg S, Venkatesh P, Mithal C, Vohra R, Mehrotra A. Intravitreal bevacizumab for subfoveal idiopathic choroidal neovascularization. Arch Ophthalmol 2007;125:1487-92. (Pubitemid 350106680)
15. Cohen SY, Laroche A, Leguen Y, Soubrane G, Coscas GJ. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103:1241-4. (Pubitemid 26282507)
16. Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004;30:287-90.
17. Chan WM, Lai TY, Liu DT, Lam DS. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 2007;143:977-83.
18. Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344-9. (Pubitemid 44702055)
19. Garg S, Brod R, Kim D, Lane RG, Maguie J, Fischer D. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration. Clin Experiment Ophthalmol 2008;36:252-6. (Pubitemid 351560274)
20. Kumar A, Prakash G, Singh RP. Transpupillary thermotherapy for idiopathic subfoveal choroidal neovascularization. Acta Ophthalmol Scand 2004;82:205-8. (Pubitemid 38515379)